×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Announces Webcast of First Quarter 2003 Financial Results

FOR IMMEDIATE RELEASE

FOR IMMEDIATE RELEASE

THOUSAND OAKS, Calif. -- April 4, 2003 -- Amgen (NASDAQ:AMGN) today announced that it will report first quarter 2003 financial results on Tuesday, April 22, 2003, after the financial markets close. The announcement will be followed by a conference call at 2:00 PM (PDT) with the investment community, featuring Kevin Sharer, Chairman and Chief Executive Officer, and other members of Amgen's senior management.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call is expected to last approximately one hour.

This event can be accessed by going to Amgen's website, www.amgen.com, and clicking on Investor Center, then on Amgen Events. The event will be archived and available for replay for 72 hours after the event.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology.

CONTACT: Amgen, Thousand Oaks

Jeff Richardson, 805/447-3227 (media)

Cary Rosansky, 805/447-4634 (investors)

EDITOR'S NOTE: An electronic version of this news release may be accessed via our web site at www.amgen.com. Visit the Corporate Center and click on Amgen News.